Hologic, Inc. (NASDAQ:HOLX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

According to Zacks, “Hologic’s third-quarter 2017 performance was quite promising with revenues and earnings beating the Zacks Consensus Estimate. The company’s top-line growth was led by strength in the molecular diagnostics and GYN Surgical businesses. Moreover, sales were driven by the company’s recent receipt of CE mark for its new Panther Fusion system and Panther Fusion assays for flu and respiratory testing. Also, the company’s strong cash position is another encouraging factor. On the flip side, Hologic has been trading below the broader industry over the last six months. Moreover, the lowered guidance suggests dull prospects. Furthermore, the blood screening divestiture is expected to impede the company’s growth momentum in the days ahead. Foreign currency headwinds and a competitive landscape also continue to pose challenges.”

A number of other research analysts have also issued reports on HOLX. Royal Bank Of Canada reduced their target price on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a research note on Thursday. Deutsche Bank AG reduced their target price on shares of Hologic from $51.00 to $49.00 and set a “buy” rating for the company in a research note on Thursday. Jefferies Group LLC set a $49.00 target price on shares of Hologic and gave the company a “buy” rating in a research note on Sunday, May 28th. BidaskClub lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating on shares of Hologic in a research note on Tuesday, August 1st. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $48.64.

Hologic (NASDAQ:HOLX) traded down 1.65% on Friday, reaching $39.25. 5,768,147 shares of the company traded hands. The company has a 50-day moving average price of $45.06 and a 200-day moving average price of $42.98. Hologic has a 12 month low of $35.15 and a 12 month high of $46.80. The company has a market capitalization of $11.01 billion, a P/E ratio of 14.62 and a beta of 0.90.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.01. The firm had revenue of $806.10 million during the quarter, compared to analyst estimates of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. Hologic’s revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.51 EPS. Equities research analysts expect that Hologic will post $2.01 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/06/hologic-inc-nasdaqholx-lifted-to-hold-at-zacks-investment-research.html.

In other news, Director Elaine Ullian sold 8,938 shares of the company’s stock in a transaction that occurred on Friday, June 2nd. The shares were sold at an average price of $43.99, for a total value of $393,182.62. Following the completion of the sale, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $1,047,401.90. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Peter J. Valenti III sold 10,005 shares of the company’s stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $43.44, for a total transaction of $434,617.20. Following the completion of the sale, the insider now directly owns 20,994 shares of the company’s stock, valued at $911,979.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,562 shares of company stock valued at $2,802,013. Company insiders own 0.79% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in HOLX. Stratos Wealth Partners LTD. increased its stake in Hologic by 0.6% in the second quarter. Stratos Wealth Partners LTD. now owns 4,954 shares of the medical equipment provider’s stock worth $225,000 after buying an additional 30 shares during the last quarter. Cleararc Capital Inc. increased its stake in Hologic by 1.1% in the first quarter. Cleararc Capital Inc. now owns 6,843 shares of the medical equipment provider’s stock worth $291,000 after buying an additional 77 shares during the last quarter. Compton Capital Management Inc. RI increased its stake in Hologic by 0.6% in the first quarter. Compton Capital Management Inc. RI now owns 16,810 shares of the medical equipment provider’s stock worth $715,000 after buying an additional 100 shares during the last quarter. Advantus Capital Management Inc increased its stake in Hologic by 0.4% in the first quarter. Advantus Capital Management Inc now owns 27,936 shares of the medical equipment provider’s stock worth $1,189,000 after buying an additional 116 shares during the last quarter. Finally, Shell Asset Management Co. increased its stake in Hologic by 0.7% in the first quarter. Shell Asset Management Co. now owns 24,647 shares of the medical equipment provider’s stock worth $1,049,000 after buying an additional 182 shares during the last quarter. Institutional investors and hedge funds own 94.32% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.